| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.2011.633511 |
| P698 | PubMed publication ID | 22077833 |
| P50 | author | Ethan Rubinstein | Q16105613 |
| G Ralph Corey | Q115862748 | ||
| Martin E Stryjewski | Q115862786 | ||
| P2093 | author name string | Zeina A Kanafani | |
| P2860 | cites work | Red man syndrome | Q21195101 |
| Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 | ||
| Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus | Q24556635 | ||
| Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia | Q28286874 | ||
| Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms | Q28374448 | ||
| Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis | Q33390834 | ||
| Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects | Q33554391 | ||
| Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus | Q34077052 | ||
| Intrapulmonary pharmacokinetics of linezolid | Q34106719 | ||
| In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp | Q34141027 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 | ||
| Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study | Q34268116 | ||
| Tissue penetration of telavancin after intravenous administration in healthy subjects | Q34352132 | ||
| Vancomycin: a history | Q34472263 | ||
| Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study | Q34509652 | ||
| Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens | Q34699108 | ||
| Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients | Q34991274 | ||
| Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients | Q35808723 | ||
| Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus | Q36095086 | ||
| Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. | Q36282000 | ||
| The pharmacokinetic and pharmacodynamic properties of vancomycin | Q36328971 | ||
| In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative | Q46634713 | ||
| Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum | Q46772621 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006). | Q46867668 | ||
| Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. | Q46878727 | ||
| Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. | Q53544946 | ||
| Pulmonary disposition of vancomycin in critically ill patients. | Q54374101 | ||
| Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics | Q36422696 | ||
| Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). | Q36660619 | ||
| Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria | Q36670352 | ||
| Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States | Q36744770 | ||
| Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia | Q36856249 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Interpretation of antibiotic concentration ratios measured in epithelial lining fluid | Q36936597 | ||
| Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections | Q37117865 | ||
| Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-pheno | Q37144809 | ||
| Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole | Q37274678 | ||
| Defining, treating and preventing hospital acquired pneumonia: European perspective | Q37319452 | ||
| Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. | Q37392917 | ||
| Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. | Q37859444 | ||
| Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection | Q38371341 | ||
| Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation | Q39686295 | ||
| In vitro activity of TD-6424 against Staphylococcus aureus | Q40130630 | ||
| Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 | ||
| Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus | Q41814975 | ||
| Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters | Q41831644 | ||
| Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. | Q42049579 | ||
| Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers | Q42576977 | ||
| Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model | Q42627265 | ||
| Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia | Q42822939 | ||
| Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia | Q42905478 | ||
| Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia | Q42905606 | ||
| Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008). | Q42991022 | ||
| Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects | Q43184655 | ||
| Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria | Q43553034 | ||
| Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams | Q43681777 | ||
| Risk factors and treatment outcomes in osteomyelitis | Q43727524 | ||
| Intrapulmonary penetration of linezolid | Q44440587 | ||
| Penetration of vancomycin into human lung tissue | Q44470518 | ||
| Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia | Q44647040 | ||
| Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria | Q44803993 | ||
| Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women | Q44935039 | ||
| Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects | Q44938149 | ||
| Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses | Q44975087 | ||
| Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). | Q45013095 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin | Q46489824 | ||
| Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact | Q46494181 | ||
| Telavancin: in vitro activity against staphylococci in a biofilm model | Q46561648 | ||
| Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia | Q46589068 | ||
| Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia | Q46620650 | ||
| Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms | Q46620675 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pneumonia | Q12192 |
| hospital-acquired infection | Q215509 | ||
| gram-positive bacteria | Q857288 | ||
| P304 | page(s) | 2737-2750 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia | |
| P478 | volume | 12 |
| Q34390763 | Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. |
| Q33429168 | Safety profiles of old and new antimicrobials for the treatment of MRSA infections. |
| Q28078557 | Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer? |
| Q38522574 | Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections |
| Q35905561 | Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA). |
| Q33788308 | Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens |
| Q38159966 | Telavancin: a review of its use in patients with nosocomial pneumonia |
| Q34433066 | Vancomycin revisited - 60 years later |
Search more.